Conversely in HCV-infected patients with resolved HBV infection, non-HCV infected patients with HBV reactivation during anti-cancer/immunosuppressive therapy or BMT had significantly higher IL-1β levels than did those without HBV reactivation. Here, IL1B is linked to cancer.